Tempus AI Stock (TEM) Surges 40% in a Week — Is More Upside Ahead?
Shares of Tempus AI ($TEM) jumped 15% Thursday, extending their five-day gain to nearly 40%. The rally came after CEO Eric Lefkofsky outlined the c...
Astrazeneca Plc (AZN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Gotham Asset Management Joel Greenblatt | 0 | $0 | 0% | |
| 2. | NWI Management Hari Hariharan | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $160.57 | 20 | $3,248.81 | 19,288 | 2026-08-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $185.78 | 11,893 | $2,209,481.54 | 19,262 | 2026-05-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 487,420 | $92,316,944 | 0.79% | |
| 2. | 179,593 | $34,054,410 | 0.08% | |
| 3. | 46,736 | $8,862,080 | 1.35% | |
| 4. | 44,270 | $8,284,761 | 0.86% | |
| 5. | 23,593 | $4,473,705 | 0.45% |
News See All
AstraZeneca (AZN)'s Lung Drug Delivers the Good News its Pipeline Needed
On September 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary disease...
AstraZeneca (AZN) Wins FDA Approval for its Breast Cancer Pill After Regulators Voiced Doubts
On September 5, 2026, Bloomberg reported that the FDA granted accelerated approval to AstraZeneca PLC (NYSE:AZN)’s camizestrant, sold as Etcamah, for a genetically driven form of metastatic breast cancer...
AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss
AstraZeneca PLC (NYSE:AZN)'s breast cancer pill Etcamah (camizestrant) failed to meet the primary endpoint in the Phase III SERENA-4 trial, dealing a setback to one of the company’s key oncology growth...
Jim Cramer Says He Is Not Going to Put His Money on AstraZeneca (AZN)
Toward the end of the lightning round on September 8, when a caller inquired about AstraZeneca PLC (NYSE:AZN), Mad Money host Jim Cramer commented: Alright, now, AstraZeneca reminds me of a company, it...
Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion?
AstraZeneca plc (NASDAQ:AZN) is exploring whether one of its biggest cancer drugs can work better with a carefully selected partner.
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory.
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss
Ionis Pharmaceuticals, Inc. ($IONS) shares dropped about 10% in premarket trading after a large cardiovascular trial of pelacarsen, a drug develope...
AstraZeneca Stock (AZN) Slides Despite New Esophagus Drug Trial Success
Shares in pharmaceuticals giant AstraZeneca ($AZN) and peer Amgen ($AMGN) both dropped in pre-market trading despite hailing successful trial resul...
Hedge Fund Resource Center